CRISPR is a gene-editing technology that allows researchers to alter DNA sequences and modify gene function. It is useful in gene editing. The main types of products in CRISPR technology are design tools, plasmid and vector, CAS9 and G-RNA and delivery system products. CRISPR-Cas9 is a groundbreaking technology that allows geneticists and medical researchers to edit portions of the genome by removing, inserting, or changing DNA sequences. The different applications include genome editing or genetic engineering, genetically modified organisms, agricultural biotechnology, others and are used by several sectors such as industrial biotech, biological research, agricultural research, therapeutics and drug discovery. The CRISPR technology market research report is one of a series of new reports from The Business Research Company that provides CRISPR technology market statistics, including CRISPR technology industry global market size, regional shares, competitors with a CRISPR technology market share, detailed CRISPR technology market segments, market trends and opportunities, and any further data you may need to thrive in the CRISPR technology industry. This CRISPR technology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global crispr technology market size will grow from $1.33 billion in 2022 to $1.65 billion in 2023 at a compound annual growth rate (CAGR) of 24.6%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global crispr technology market size is expected to grow to $3.77 billion in 2027 at a CAGR of 22.9%. The application of CRISPR technology as a diagnostic tool is expected to boost the market during the period. The Sherlock CRISPR SARS-CoV-2 kit is the first diagnostic kit based on CRISPR technology for infectious diseases caused due to COVID-19. In May 2020, FDA announced the emergency use authorization to the Sherlock BioSciences Inc’s Sherlock CRISPR SARS-CoV-2 kit which is a CRISPR-based SHERLOCK (Specific High-sensitivity Enzymatic Reporter unLOCKing) diagnostic test. This test helps in specifically targeting RNA or DNA sequences of the SARS-CoV-2 virus from specimens or samples such as nasal swabs from the upper respiratory tract and fluid in the lungs from bronchoalveolar lavage specimens. This diagnostic kit has high specificity and sensitivity and does not provide false negative or positive results. Widening the application of CRISPR technology for the diagnosis of infectious diseases will increase the demand for CRISPR technology products and services. Stringent government regulations are expected to retard the growth of the CRISPR technology market during the period. There is no existence of internationally agreed regulatory framework for gene editing products and countries are in the process of evaluating whether and to what extent current regulations are adequate for research conducted with gene editing and applications and products related to gene editing. The Court of Justice of the European Union ruled that it would treat gene-edited crops as genetically modified organisms, subject to stringent regulation. According to an article of 2020, in India, as per the National Guidelines for Stem Cell Research, genome modification including gene-editing by CRISPR-Cas9 technology of stem cells, germ-line stem cells or gamete and human embryos is restricted only to in-vitro studies. Thus, strict regulations by the government present a threat to the growth of the market. Several advancements in CRISPR technology are trending in the market during the period. Advancements in technology will help in reducing errors, limiting unintended effects, improving the accuracy of the tool, widening its applications, developing gene therapies and more. In 2020, astudy in Springer Nature stated that researchers have used enzyme engineering to boost the accuracy of the technique of error-prone CRISPR–Cas9 system to precisely target DNA without introducing as many unwanted mutations. The advancements in CRISPR technology will result in better tools that are capable of providing better outcomes. In March 2021, Integrated DNA Technologies (IDT), a US-based genomics solutions provider, acquired Swift Biosciences. The acquisition aimed at leveraging Swift's academic and clinical research in next-generation sequencing. Swift Biosciences is a US-based company involved in creating genomics kits to prepare Next-Generation Sequencing (NGS) libraries. Major players in the market are Thermo Fisher Scientific, GenScript Biotech Corporation, CRISPR Therapeutics AG, Editas Medicine, Horizon Discovery PLC., Integrated DNA Technologies Inc. (Danaher), Origene Technologies Inc., Transposagenbio Biopharmaceuticals (Hera Biolabs), Intellia Therapeutics Inc. and GeneCopoeia Inc. North America was the largest region in the CRISPR technology market in 2022. Western Europe was the second largest region in the global CRISPR technology market. The regions covered in the global CRISPR technology market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The CRISPR technology market includes revenue earned by CRISPR Screening Libraries, CRISPR Positive Controls, CRISPR Negative Controls, and Gene-specific Knockout Kits. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global crispr technology market is segmented - 1) By Product Type: Design Tools, Plasmid And Vector, Cas9 And G-RNA, Delivery System Products 2) By Application: Genome Editing/ Genetic Engineering, Genetically Modified Organisms, Agricultural Biotechnology, Other Applications 3) By End-User: Industrial Biotech, Biological Research, Agricultural Research, Therapeutics And Drug Discovery

Antimicrobial susceptibility testing (AST) is a laboratory procedure done by clinical laboratory professionals to identify which antimicrobial specimen is specifically effective for individual patients. The antimicrobial susceptibility testing market consists of sales of antimicrobial susceptibility testing by entities (organizations, sole traders and partnerships) that are engaged in laboratory services that provide antimicrobial susceptibility testing. The main types of antimicrobial susceptibility testing (AST) procedures are antibacterial testing, antifungal testing, antiparasitic testing and others. Antifungal susceptibility testing refers to the ability of a specific organism to grow in vitro in the presence of a particular drug. AST products that are used in the testing are manual antimicrobial susceptibility testing products, automated laboratory instruments, and other consumables. These are used for diagnostics, drug discovery and development, and epidemiology. Antimicrobial susceptibility testing is used by hospitals and diagnostic centres, pharmaceutical and biotechnology companies, research and academic institutes, and clinical research organizations (CROs). The antimicrobial susceptibility testing market research report is one of a series of new reports from The Business Research Company that provides antimicrobial susceptibility testing market statistics, including antimicrobial susceptibility testing industry global market size, regional shares, competitors with an antimicrobial susceptibility testing market share, detailed antimicrobial susceptibility testing market segments, market trends and opportunities, and any further data you may need to thrive in the antimicrobial susceptibility testing industry. This antimicrobial susceptibility testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global antimicrobial susceptibility testing market size grew from $3.67 billion in 2022 to $3.91 billion in 2023 at a compound annual growth rate (CAGR) of 6.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The antimicrobial susceptibility testing market size is expected to grow to $4.94 billion in 2027 at a CAGR of 6.0%. The rising incidence of infectious diseases globally contributed to the growth of the antimicrobial susceptibility testing market. Infectious diseases are caused by organisms like bacteria, viruses, fungi and parasites. Diseases caused by bacteria are bacterial pneumonia, tuberculosis, the virus smallpox, AIDS and others. According to World Health Organization (WHO), in 2021, , an estimated 10.6 million people are infected with tuberculosis globally, 1.6 million died , and 1.5 million people acquired HIV in 2021 while 650,000 people lost lives due to it. This increase in the incidence of infected people boosted the use of susceptibility testing of the organisms to develop the most effective drugs and this, in turn, drove the market for antimicrobial susceptibility testing. Rapid antimicrobial susceptibility testing is increasingly being used to avoid misuse of antibiotics and to provide effective treatment and this is emerging as a key trend in the antimicrobial susceptibility testing market. There are many ways to perform antimicrobial susceptibility testing in minutes or a few hours. FISH (Fluorescence in situ hybridization) is mostly used in rapid antimicrobial susceptibility testing. The PNA-FISH applies peptide nucleic acid probes that allow rapid and specific binding, this process is applied in QuickFish technology (OpGen) which performs identification of microbial by targeting 16s RNA. For instance, the antimicrobial susceptibility testing system by Genefluidics Inc measures bacterial growth by quantifying 16s rRNA molecules using an electrochemical biosensor. Major players in the antimicrobial susceptibility testing market are BioMérieux SA, Becton, Dickinson and Company, Thermo Fisher Scientific, Danaher Corporation, Bio-Rad Laboratories, Accelerate Diagnostics, Hi-Media Laboratories, Creative Diagnostics, Merck KGaA, Roche Diagnostics Limited, BD, Alifax Holding S.p.A., Synbiosis, Zhuhai DL Biotech Co, Mast Group, ELITechGroup, Genefluidics, Mast Group, CONDALAB, and QuantaMatrix. North America was the largest region in the antimicrobial susceptibility testing market in 2022. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the antimicrobial susceptibility testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the antimicrobial susceptibility testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The antimicrobial susceptibility testing (AST) market includes revenues earned by dilution susceptibility tests and disc diffusion susceptibility tests. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global antimicrobial susceptibility testing market is segmented - 1) By Type: Antibacterial Testing, Antifungal Testing, Antiparasitic Testing, Other Types 2) By Products: Manual Antimicrobial Susceptibility Testing Products, Automated Laboratory Instruments, Consumables 3) By Application: Diagnostics, Drug Discovery and Development, Epidemiology, Other Applications 4) By End User: Hospitals And Diagnostic Centers, Pharmaceutical And Biotechnology Companies, Research And Academic Institutes, Clinical Research Organizations (CROs)

Ultraviolet-visible spectroscopy is a method used to measure light absorbance in the ultraviolet and visible ranges of the electromagnetic spectrum. The ultraviolet-visible spectroscopy devices find their application in analytical chemistry for the quantitative determination of different analytes, such as transition metal ions, highly conjugated organic compounds, and biological macromolecules. The different types of instruments included in ultraviolet-visible spectroscopy are single-beam systems, double-beam systems, array-based systems, and handheld systems. Single-beam system utilizes one beam of light that passes through the sample, and the intensity of the light reflected from a reference is measured without the sample. Double-beam spectroscopes calculate the sample and conduct blank adjustments using the sample and reference beams. Array-based systems use array detectors that can simultaneously acquire an entire spectral image over a finite spectral region. Handheld systems allow researchers to analyze samples on the spot. Ultraviolet-visible spectroscopy is implemented in a wide range of verticals, such as pharmaceutical and biotechnology companies, academic and research institutes, agriculture and food industries, and environmental testing labs, and is used in industrial applications, physical chemistry studies, life science studies, environmental studies, academic applications, life science research and development, quality assurance, and quality control. The ultraviolet-visible spectroscopy market research report is one of a series of new reports from The Business Research Company that provides ultraviolet-visible spectroscopy market statistics, including ultraviolet-visible spectroscopy industry global market size, regional shares, competitors with a ultraviolet-visible spectroscopy market share, detailed ultraviolet-visible spectroscopy market segments, market trends and opportunities, and any further data you may need to thrive in the ultraviolet-visible spectroscopy industry. This ultraviolet-visible spectroscopy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global ultraviolet-visible spectroscopy market size grew from $1.42 billion in 2022 to $1.49 billion in 2023 at a compound annual growth rate (CAGR) of 5.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services, causing inflation across goods and services and affecting many markets across the globe. The ultraviolet-visible spectroscopy market size is expected to grow to $1.83 billion in 2027 at a CAGR of 5.3%. The outbreak of COVID-19 led to increase in the production of pharmaceutical drugs and the demand for vaccines and fueled the growth of the ultraviolet-visible spectroscopy market. Due to the increased demand for certain drugs during the pandemic, the demand for ultraviolet-visible spectroscopy instruments also grew for research and development of new medications and vaccines. UV Vis spectrophotometry provides fast, easy, and accurate characterization of components such as nucleic acids, proteins, and additives/preservatives and can impact the time-to-result for both downstream and upstream processes, including quality control. According to a study by Mettler Toledo, these instruments were extremely crucial for the development of the COVID-19 vaccines and thus supported the growth of the market. Companies in the market are increasingly investing in the handheld or portable ultraviolet-visible spectroscopy market, which allows consumers to take informed decisions on the spot, thus saving valuable time. Major companies operating in the ultraviolet-visible spectroscopy sector are focused on developing portable technological solutions for ultraviolet-visible spectroscopy. For instance, in April 2020, ERWEKA GmbH, a German analytical manufacturer and supplier of tablet testing equipment, launched Dissolution Online UV-Vis System, which can integrate with the Thermo Scientific Evolution 350 spectrophotometer. ERWEKA has fully integrated the Thermo Scientific Evolution 350 into its software, Disso.NET dissolution, enabling half automation (with the Dissolution Online System) and even full automation (with RoboDis II) dissolution testing and additionally with integrated UV-Vis analysis. With Disso.NET, customers can manage all UV-Vis dissolution tests in one software with the photometer fully integrated. In April 2020, Wiley, a US-based company focusing on academic publishing and instructional materials, acquired Bio-Rad Laboratories informatics products, including the company spectroscopy software and spectral databases, for an undisclosed amount. This acquisition adds expertise, content, and powerful software to Wiley's science solutions segment. Bio-Rad Laboratories is a USA-based manufacturer and distributor of life science research products, clinical diagnostics, and analytical instrumentation. Major players in the ultraviolet-visible spectroscopy market are Shimadzu Corporation, Agilent Technologies, Thermo Fisher Scientific Inc., PerkinElmer Inc., Bio-Rad Laboratories, Hitachi High-Technologies Corporation, Buck Scientific, Bruker Corporation, Mettler-Toledo, Cole-Parmer, GBC Scientific Equipment, Hach Company, HORIBA. Ltd., Hamamatsu Photonics K.K, Analytik Jena, GBC Scientific Equipment, Biochrom, Ametek Process Instruments, Cecil Instrument, and GE Healthcare. North America was the largest region in the ultraviolet-visible spectroscopy market in 2022. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the ultraviolet-visible spectroscopy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the ultraviolet-visible spectroscopy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The ultraviolet-visible spectroscopy market consists of sales of spectrum machine, wavelength selector, detector, signal processor. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global ultraviolet visible spectroscopy market is segmented - 1) By Instrument type: Single-Beam System, Double-Beam System, Array Based System, Handheld System 2) By Application: Industrial Applications, Physical Chemistry Studies, Life Science Studies, Environmental Studies, Academic Applications, Life Science Research and Development, Quality Assurance and Quality Control 3) By End User: Pharmaceutical And Biotechnology Companies, Academic And Research Institutes, Agriculture And Food Industries, Environmental Testing Labs

The mycoplasma testing detects mycoplasma pneumoniae, which causes mycoplasma pneumonia. Mycoplasma pneumonia is a contagious respiratory infection that spreads easily through contact with respiratory fluids. It can cause epidemics. Mycoplasma testing includes a group of tests that measures antibodies in the blood produced in response to a mycoplasma infection and detects the microbe directly through detecting or culturing its genetic material (DNA) in a body sample. The main types of mycoplasma testing technologies include polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), enzymatic methods, and deoxyribonucleic acid (DNA) staining. Polymerase chain reaction (PCR) detects mycoplasma species using primers specific for mycoplasma DNA, usually mycoplasma 16S rRNA genes. Enzyme-linked immunosorbent assay (ELISA) detects the presence of mycoplasma using either antibodies, or labeled probes for the mycoplasma 16S rRNA genes. Enzymatic methods use a sample of the suspected cell culture which converts ADP to ATP using mycoplasmal enzymes. Deoxyribonucleic acid (DNA) staining detects the mycoplasma strain M. hyorhinis by growing a sample of suspected cell cultures with Vero cells, and staining the cells for DNA using a fluorescent dye. The different products in mycoplasma testing include instruments, assay, kits, and reagents. Mycoplasma testing is applied in cell line testing, virus testing, and end- of- production cell testing and is used by pharmaceutical & biotechnology companies, cell banks & laboratories, contract research organizations, academic research institutes. The mycoplasma testing market research report is one of a series of new reports from The Business Research Company that provides mycoplasma testing market statistics, including mycoplasma testing industry global market size, regional shares, competitors with a mycoplasma testing market share, detailed mycoplasma testing market segments, market trends and opportunities, and any further data you may need to thrive in the mycoplasma testing industry. This mycoplasma testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global mycoplasma testing market size grew from $0.81 billion in 2022 to $0.92 billion in 2023 at a compound annual growth rate (CAGR) of 13.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The mycoplasma testing market size is expected to grow to $1.47 billion in 2027 at a CAGR of 12.5%. The prevalence of mycoplasma pneumonia co-infection among patients with COVID-19 is expected to boost the market for mycoplasma testing in the forecast period. The presence of co-infection of M. pneumonia increases the need to test patients with COVID-19, increasing demand for routine diagnostic tests for respiratory pathogens like M. pneumonia. The coinfections in COVID-19 cases has a significant probability of them being caused by Mycoplasma pneuminiae. For instance, according to a 2020 study published in the Archives of Medical Laboratory Sciences, the co-infection due to M. pneumonia varied between 1 and 40.6% depending on the population and diagnostic tests used and the combined prevalence of M. pneumoniae co-infection among patients with COVID-19 was reported by 17%. The lack of skilled/trained molecular biologists is expected to restrain the growth of the market in the forecast period. Mycoplasma testing requires specialized skillsets relating to life sciences, pharmaceuticals, electronics and software. These skillsets are available to a limited number of organizations, most of which are located in the USA and Europe. Lack of trained manpower capable of performing the molecular biology experiments and interpreting the results is a major limitation in the testing and confinement of COVID-19 in developing countries. For the few laboratory experts present in these countries, priority is given to other medical emergencies such as heart attacks and road accidents. This shortage of skilled labor is expected to be a significant deterrent to the growth of the market during the forecast period. Major players operating in the market are undertaking various strategic investments such as the launch of innovative products, research and development advancements, and technological innovations, which are gaining significant popularity in the mycoplasma testing market. Companies are introducing new innovative products to meet the requirements of end-users and expand the consumer base to survive in the competitive business environment. For instance, in July 2020, bioMérieux, a France-based biotechnology company introduced Bio Fire Mycoplasma, an advanced test used for bio-therapeutics including hormones, antibodies, gene, and cell therapies for mycoplasma detection in pharmaceutical products. In January 2020, Charles River Laboratories International, Inc., a USA-based company specializing in a variety of preclinical and clinical laboratory services for the biotechnology, pharmaceuticals, and medical devices industry acquired HemaCare Corporation for approximately $380 million in cash. With the acquisition, Charles River Laboratories International, Inc. expands the scientific capabilities of the company in the high-growth cell therapy sector and HemaCare cellular products improve Charles River Laboratories ability to offer a comprehensive cell therapy solution, including mycoplasma detection. HemaCare Corporation is a USA-based company engaged in the production of human-derived biological products and services for cellular therapy development, drug discovery, and biomedical research. Major players in the mycoplasma testing market are Thermo Fisher Scientific Inc., Merck KGaA, Lonza, PromoCell GmbH, American Type Culture Collection, Charles River Laboratories International Inc., Bionique Testing Laboratories Inc., Biological Industries Israel Beit Haemek Ltd., InvivoGen, Agilent Technologies, Abbott, Roche Diagnostics, Boston Scientific Corporation, Clongen Laboratories LLC, Creative Bioarray, Nelson Laboratories Fairfield Inc., Norgen Biotek Corporation, Biotools B & M Labs S.A, GenBio, GeneCopoeia Inc., Minerva Biolabs GmbH, Mycoplasma Experience, Savyon Diagnostics, ScienCell Research Laboratories Inc., AngioDynamics, AtriCure Inc., CONMED Corporation, Olympus Corporation, Smith & Nephew, and Advanced Cardiac Therapeutics. North America was the largest region in the mycoplasma testing market in 2022. Asia-Pacific is expected to be the fastest growing region in the forecast period. The regions covered in the mycoplasma testing report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the mycoplasma Testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The mycoplasma testing market includes revenues earned by entities by PCR detection assay, indirect hoechst stain, and culture isolation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global mycoplasma testing market is segmented - 1) By Product: Instruments, Assay, Kits, and Reagents 2) By Technology: PCR, ELISA, Enzymatic Methods, DNA Staining, Other Technologies 3) By Application: Cell line Testing, Virus Testing, End- of- Production Cell Testing 4) By End User: Pharmaceutical & Biotechnology Companies, Cell Banks & Laboratories, Contract Research Organizations, Academic Research Institutes

Digital pathology is the process of use of digital imaging for pathology procedures. Digital pathology equipment converts glass slides into high-resolution digital images by utilizing slide scanner hardware, software, and services. These images can be viewed, managed, and analyzed on a computer or mobile screen. The main types of products in digital pathology include scanners, software, communication systems, and storage systems. Scanner uses of microscopic array technology to produce a three-dimensional digital representation of a pathology slide for viewing and automated image analysis. Software transfers the data into a digital medium for image review and analysis and tissue image analysis. Communication systems are used to communicate between separate whole slide acquisition, storage, and viewing components and also to remote colleagues using real-time telepathology. Storage systems consist of the digital archives of samples which allows for long-term analysis and other predictive analytics. The different types of pathology are human pathology and veterinary pathology. It is used by pharmaceutical & biotechnology companies, hospitals and reference laboratories, academic & research institutes for drug discovery, disease diagnosis, teleconsultation, and training & education. The digital pathology market research report is one of a series of new reports from The Business Research Company that provides digital pathology market statistics, including digital pathology industry global market size, regional shares, competitors with a digital pathology market share, detailed digital pathology market segments, market trends and opportunities, and any further data you may need to thrive in the digital pathology industry. This digital pathology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global digital pathology market size grew from $0.89 billion in 2022 to $0.99 billion in 2023 at a compound annual growth rate (CAGR) of 11.2%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The digital pathology market size is expected to grow to $1.65 billion in 2027 at a CAGR of 13.7%. The increased prevalence of cancer contributed to the growth of the digital pathology market. Digital pathology allows patients to accelerate the diagnosis and treatment of cancer, and thus in increase in cancer cases is driving the growth of the market. according to the 2021 American Cancer Society report, 1.8 million new cases of cancer diagnosed were diagnosed in 2020. There is a rise in the number of cancer cases due to the growing elderly population globally coupled with unhealthy lifestyles. Increasing incidences of cancer increases the demand for digital pathology as it makes it easier to access the image faster, view all relevant information, and help diagnose faster. The lack of trained pathologists acted as a restrain for the digital pathology market in the historic period. Pathologists are critical in performing laboratory tests essential for disease diagnosis as pathologists need to examine samples and interpret medical laboratory tests for patients to receive proper treatment. There is a dearth of pathologists in the Asia-Pacific region and countries in Africa. For instance, In February 2022, according to a forensic magazine report, 217 bodies were waiting to be examined by the state's forensic pathologists, and the figure might rise to 300 in less than two weeks. Moreover, more than 200 bodies were waiting for autopsies. The launch of endoscopy systems with artificial intelligence (AI) is gaining popularity in the digital pathology market. Artificial intelligence-based systems have been advanced to anatomize endoscopic images. They identify neoplasms with high accuracy and low interobserver variation. For instance, in April 2020, Olympus Corporation declared the launch of EVIS X1, an AI based endoscopy system. The new system helps derive outcomes from disorders of the stomach, colon, and esophagus, as well as from bronchial diseases, and makes work easier for endoscopist. In October 2020, Cyted Ltd., a UK-based company providing digital diagnostic infrastructure, acquired Pathognomics Limited for an undisclosed amount. The acquisition of Pathognomics gave Cyted access to a digital pathology platform and an approved laboratory setting, allowing Cyted to quickly adapt and develop its pipeline of innovative biomarkers and artificial intelligence (AI) technology. Pathognomics Limited is a UK-based provider of digital pathology and clinical diagnostic laboratory services. Major players in the digital pathology market are Leica Biosystems, Koninklijke Philips N.V., 3D-Histech Ltd., Apollo Enterprise Imaging, F. Hoffmann-La Roche Ltd., Visiopharm A/S, Hamamatsu Photonics K.K., Corista, Ventana Medical Systems, Inc., Huron Digital Pathology Inc., Indica Labs, Inc., and Olympus Corporation of the Americas, Objective Pathology Services, and XIFIN. North America was the largest region in the digital pathology market in 2022. Asia-Pacific was the second largest region in the digital pathology market. The regions covered in the digital pathology report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The digital pathology market consists of the sales of slide scanners, software, and reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global digital pathology market is segmented - 1) By Product: Scanners, Software, Communication Systems, Storage Systems 2) By Type: Human Pathology, Veterinary Pathology 3) By End User: Pharmaceutical & Biotechnology Companies, Hospitals and Reference Laboratories, Academic & Research Institutes 4) By Application: Drug Discovery, Disease Diagnosis, Teleconsultation, Training & Education

Fetal bovine serum refers to a typical element of animal cell culture media that is utilised to support the growth of eukaryotic cells cultured in vitro. It is obtained by harvesting bovine foetuses from pregnant cows who were about to be slaughtered. FBS is frequently obtained with a cardiac puncture without the use of any type of anaesthesia. The main types of fetal bovine serum are charcoal stripped, chromatographic, dialyzed fetal bovine serum, exosome depleted, stem cell, others. Charcoal-stripped fetal bovine serum has activated carbon that helps lower levels of lipophilic compounds such as hormones, growth factors, and steroids and is used to conduct receptor or estrogen related studies. Dialyzed fetal bovine serum has reduced concentration of low molecular weight components such as nucleotides, amino acids, hormones, salts and various small proteins in serum and is used in cell culture systems requiring a more defined environment of small molecules. Exosome depleted fetal bovine serum isolates exosomes from cultured cells without the complication of bovine exosomes that are present in conventional FBS and is used for research on exosomes. The fetal bovine serum is used in drug discovery, cell culture media, in vitro fertilization, human and animal vaccine production, diagnostics, others. Fetal bovine serum is used in various sectors including research and academic institutes, biotechnology and pharmaceutical industry, others. The fetal bovine serum market research report is one of a series of new reports from The Business Research Company that provides fetal bovine serum market statistics, including fetal bovine serum industry global market size, regional shares, competitors with a fetal bovine serum market share, detailed fetal bovine serum market segments, market trends and opportunities, and any further data you may need to thrive in the fetal bovine serum industry. This fetal bovine serum market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global fetal bovine serum market size grew from $1010 million in 2022 to $1067.44 million in 2023 at a compound annual growth rate (CAGR) of 5.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The fetal bovine serum market size is expected to grow to $1419.98 million in 2027 at a CAGR of 7.4%. The increase in demand for biopharmaceuticals is expected to drive the growth of the fetal bovine serum market in the forecast period. A biopharmaceutical is a medicinal product that is derived from biological sources such as animals, humans, and microorganisms using biotechnology. Fetal bovine serum (FBS) is the most widely used substitute for animal cell culture media. Pharmaceutical firms, diagnostic laboratories, and researchers rely heavily on FBS for much of their cell culture requirements in biologics research. The global biologics market is expected to increase from $253.4 billion in 2020 to $420.5 billion by 2025. Therefore, the rising demand for biopharmaceuticals propels the growth of the fetal bovine serum market. Increasing collaborations between companies and research intuitions is a key trend gaining popularity in the fetal bovine serum market. Major companies are collaborating for increasing production capabilities, expanding market share and developing new products. For instance, US based GE Healthcare collaborated with New Zealand based Oritain for developing an independent test that can confirm the country of origin of fetal bovine serum (FBS) which would help biomanufacturing entities as FBS used in different countries pose different risk levels for virus contamination. Sartorius, a German-based life science research and biopharmaceutical company acquired Biological Industries for $53.67 million. Through this acquisition, Sartorius expanded cell culture media and complementing the product portfolio for the users in the growing advanced therapies market in the majority portion of Biological Industries. Biological Industries is an Israel-based chemical and biotechnology company that provides fetal bovine serum for mammalian cell culture. Major players in the fetal bovine serum market are Sartorius AG, GE Healthcare, PAN- Biotech, Thermo Fisher Scientific Inc., Biowest, Bio-Techne, Rocky Mountain Biologicals Inc., Merck KGaA, TCS Biosciences Ltd., Bovogen Biologicals Pty Ltd., Tissue Culture Biologicals, Atlanta Biologicals Inc., Atlas Biologicals, Acess Biologicals, Animal Technologies Inc., Nucleus Biologics, Corning Incorporated, J R Scientific Inc., Cytiva, Axil Scientific Pte Ltd., and Moregate Biotech. North America was the largest region in the fetal bovine serum market in 2022. Asia-Pacific recorded the fastest growth during the forecast period. The regions covered in the fetal bovine serum report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the Fetal Bovine Serum market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The fetal bovine serum market consists of sales of Ultra-low IgG, ES Cell, MSC and Exosome-Depleted. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global fetal bovine serum market is segmented - 1) By Product: Charcoal Stripped, Chromatographic, Dialyzed Fetal Bovine Serum, Exosome Depleted, Stem Cell, Other Products  2) By Application: Drug Discovery, Cell Culture Media, In Vitro Fertilization, Human and Animal Vaccine Production, Diagnostics, Other Applications 3) By End-User: Research and Academic Institutes, Biotechnology and Pharmaceutical Industry, Other End-Users

Live cell imaging is a technique of in vivo imaging of living cells for diagnosis and treatment purpose. Live cell imaging equipment helps in providing a detailed study of internal structures and cellular processes for understanding the cellular structures of cell biology. The main types of live cell imaging products include equipment, consumables, and software. The technologies used in live cell imaging are time-lapse microscopy, fluorescence recovery after photobleaching (FRAP), fluorescence resonance energy transfer (FRET), high content screening (HCS), etc. Live cell imaging finds its applications in cell biology, developmental biology, stem cell and drug discovery, others. It is used in various sectors, including pharmaceutical and biotechnology companies, academic and research institutes, and contract research organizations (CROs). The live cell imaging market research report is one of a series of new reports from The Business Research Company that provides live cell imaging market statistics, including live cell imaging industry global market size, regional shares, competitors with a live cell imaging market share, detailed live cell imaging market segments, market trends and opportunities, and any further data you may need to thrive in the live cell imaging industry. This live cell imaging market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global live cell imaging market size grew from $3.75 billion in 2022 to $4.15 billion in 2023 at a compound annual growth rate (CAGR) of 10.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The live cell imaging market size is expected to grow to $6.22 billion in 2027 at a CAGR of 10.6%. The rising incidence of cancer is expected to drive the growth of the live cell imaging market in the forecast period. Cancer is the second major cause of death worldwide, accounting for one out of every six deaths each year. For example, cancer cases are projected to increase to 29.5 million and cancer-related deaths to 16.4 million worldwide by 2040. In the United States, there were 16.9 million cancer patients in 2019, with the number expected to rise to 22.2 million by 2030. Live cell imaging technology plays a crucial role in the advancement and validation of cancer immunotherapy through visualization, characterization, and evaluation of the biological process of living cells. Therefore, the rising incidence of cancer fuels the growth of the live cell imaging market. Lack of skilled professionals is predicted to restraint the growth of the live cell imaging market. Live cell imaging technology requires highly skilled professionals to understand and study the functions of cells. According to Healthcare-in-Europe.com, an online platform that provides trends in medical technology, innovative procedures and advances in medical research, the UK and Europe are facing a serious shortage of lab skills over the next decade with medical laboratories among the worst affected. Moreover, according to the research carried out by the Gatsby Foundation, the UK will need a further 700,000 technicians to support the economy by the end of 2030. Thus, the shortage of skilled professionals is likely to hinder market growth in the coming years. In December 2020, PerkinElmer Inc., a USA-based company that focuses on diagnostics and includes capabilities of detection, imaging, informatics, and service acquired Horizon Discovery at an undisclosed amount. By combining the capabilities of Horizon with life science research of PerkinElmer and applied genomics portfolios, PerkinElmer will be able to deliver complete workflow solutions to life science customers working on drug discovery and development. Horizon Discovery is a UK-based gene-editing company. Major players in the live cell imaging market are Leica Microsystems, Olympus Corporation, Sigma-Aldrich Corporation, PerkinElmer Inc., GE Healthcare, Carl Zeiss Meditec AG, Becton Dickinson and Company, Molecular Devices LLC, Bruker Corporation, Sartorius AG, Oxford Instruments, BioTek Instruments, Etaluma Inc., and CytoSMART Technologies. North America was the largest region in the live cell imaging market in 2022.  The regions covered in the live cell imaging report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the live cell imaging market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The live cell imaging market consists of sales of light microscopes, objective lenses, accessories, and reagents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global live cell imaging market is segmented - 1) By Product: Equipment, Consumable, Software 2) By Technology: Time-Lapse Microscopy, Fluorescence Recovery After Photobleaching (FRAP), Fluorescence Resonance Energy Transfer (FRET), High Content Screening (HCS), Other Technologies 3) By Application: Cell Biology, Developmental Biology, Stem Cell and Drug Discovery, Other Applications 4) By End-User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROs)

Sample preparation is a technique that is used for converting biological and chemical products into a form that can be placed directly in analytical instruments for analysis. The different types of products in sample preparation are sample preparation instruments, consumables, and sample preparation kits. Sample preparation instrument market includes extraction systems, workstations, automated evaporation systems, liquid handling instruments, and other sample preparation instruments. It is used in proteomics, genomics, epigenomics, and others and is implemented in various sectors such as pharmaceuticals, biotechnology, molecular diagnostics, and others. The sample preparation market research report is one of a series of new reports from The Business Research Company that provides sample preparation market statistics, including sample preparation industry global market size, regional shares, competitors with a sample preparation market share, detailed sample preparation market segments, market trends and opportunities, and any further data you may need to thrive in the sample preparation industry. This sample preparation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global sample preparation market size grew from $8.11 billion in 2022 to $8.66 billion in 2023 at a compound annual growth rate (CAGR) of 6.7%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The sample preparation market size is expected to grow to $10.87 billion in 2027 at a CAGR of 5.8%. An increase in R&D spending in pharmaceuticals is expected to drive the growth of the sample preparation market in the coming years. Although pharmaceutical analyses have been performed using a variety of highly efficient analytical instruments, most sample preparation procedures are required to extract and isolate the analytes of interest from these complex matrixes because most analytical instruments cannot handle the matrix directly. The advancement of sample preparation is critical in pharmaceutical analysis, with the ultimate goal of isolating and purifying the analyte from complex matrixes. According to the National Centre for Biotechnology Information, a US-based government organization, pharmaceutical spending increased by 7.7% in 2021 to reach $576.9 billion in the US. In 2022, they forecast rises in prescription drug spending of 4.0% to 6.0% overall, 7.0% to 9.0% in clinics, and 3.0% to 5.0% in hospitals. Therefore, the increase in R&D spending in pharmaceuticals propels the growth of the sample preparation market. Players in the sample preparation industry are increasingly developing automated sample preparation systems. An automated sample preparation system uses robotics to manage the number of liquids such as reagents, specimen samples to prepare the samples for analysis and testing. These systems are integrated with software and spectrometric instruments for easy analysis of samples. For instance, in October 2020, PerkinElmer, Inc., a US-based company that enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare launched a fully automated liquid handling sample preparation and LC/MS/MS analysis workflow for testing pesticide residue in hemp and cannabis flower sample. In addition to cannabis-optimized reagents and sample prep consumables, the new end-to-end package includes proprietary cannabis SOPs and cloud-based tracking and reporting tools. In August 2021, Pacific Biosciences, a US-based biotechnology company, acquired Circulomics Inc. for an undisclosed amount. Through this acquisition, the Circulomics team will increase Pacific Biosciences' capacity for extraction and sample preparation and provide a simpler route toward an end-to-end automated workflow. Circulomics Inc. is a US-based biotechnology startup dedicated to providing highly distinctive sample preparation solutions supporting genomic workflows. Major players in the sample preparation market are Agilent Technologies, Bio-Rad Laboratories, Danaher Corporation, Illumina, Qiagen NV, PerkinElmer, F. Hoffmann-La Roche, Tecan Group Ltd., Hamilton Company, Norgen Biotek Corporation, Waters Corporation, Promega Corporation, and Biotage AB. North America was the largest region in the sample preparation market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sample preparation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the sample preparation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The sample preparation market consists of sales of solid phase extraction products, and automated instrumentation. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global sample preparation market is segmented - 1) By Product: Sample Preparation Instruments, Consumables, Sample Preparation Kit 2) By Application: Proteomics, Genomics, Epigenomics, Other Applications 3) By End User: Pharmaceutical, Biotechnology, Molecular Diagnostics, Other End Users